JSJ Pharmaceuticals, Inc. Named One of Charleston's Top Ten Innovators of the Year  
7/17/2007 9:47:41 AM

CHARLESTON, S.C., July 17 /PRNewswire/ -- JSJ Pharmaceuticals, Inc. (JSJ) is pleased to announce that it has been selected by the Charleston Regional Business Journal as one of this year's top ten innovators in the Charleston region. Among the noted innovations, JSJ has just completed the introduction of the patented PharmaDur(TM) bioadhesive technology, which has been introduced in the Umecta PD(TM) (urea 40%) and Aclaro PD(TM) (hydroquinone USP 4%) product lines.

The PharmaDur(TM) bioadhesive delivery system creates an invisible, breathable matrix providing a controlled release of medication to the applied areas. This represents an important technical advancement for the Umecta(R) and Aclaro(R) brands. Due to the controlled release of the active ingredients, PharmaDur(TM) has been shown to reduce the potential for irritation while improving the hydration of the skin. In addition to the Umecta PD(TM) and Aclaro PD(TM) brands, JSJ is working to introduce additional pharmaceutical actives utilizing the PharmaDur(TM) bioadhesive delivery technology.

"The introduction of Umecta PD(TM) and Aclaro PD(TM) is a significant breakthrough for JSJ and recognition of this innovation by the business community is a real honor," states Jonathan Alba, JSJ's Chief Operating Officer. "JSJ looks forward to additional product introductions utilizing the PharmaDur(TM) technology and the improvement it will provide to future topical drug development."

The PharmaDur(TM) technology has been made available in the following presentations:

Umecta PD(TM) (urea 40%) Emulsion -- 5oz. NDC 68712-017-03 -- 7oz. NDC 68712-017-02 Umecta PD(TM) (urea 40%) Topical Suspension -- 9oz. NDC 68712-018-02 Aclaro PD(TM) (hydroquinone 4% USP) Emulsion -- 1.5oz. NDC 68712-015-02

About JSJ Pharmaceuticals, Inc.

JSJ Pharmaceuticals, Inc. is a specialty pharmaceutical company that identifies and brings to market pharmaceutical products targeted for topical use primarily in the dermatology community. JSJ aims to be the "Next Generation" in skin-related pharmaceuticals, providing clinicians with a "toolbox" for the management of daily challenges faced in their clinical practice. To learn more, go to

Media Contact: Jon Knowles 843.965.8333 ext 104

This release was issued through eReleases(TM). For more information, visit

JSJ Pharmaceuticals, Inc.

CONTACT: Jon Knowles of JSJ Pharmaceuticals, Inc., +1-843-965-8333 ext104,